File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Explainable machine learning via intra-tumoral radiomics feature mapping for patient stratification in adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma

TitleExplainable machine learning via intra-tumoral radiomics feature mapping for patient stratification in adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma
Authors
KeywordsAdjuvant chemotherapy
NPC
Radiomics
Tumor heterogeneity map
Issue Date10-Jun-2023
PublisherSpringer-Verlag Italia
Citation
Radiologia Medica, 2023, v. 128, n. 7, p. 828-838 How to Cite?
AbstractPurpose: This study aimed to discover intra-tumor heterogeneity signature and validate its predictive value for adjuvant chemotherapy (ACT) following concurrent chemoradiotherapy (CCRT) in locoregionally advanced nasopharyngeal carcinoma (LA-NPC). Materials and methods: 397 LA-NPC patients were retrospectively enrolled. Pre-treatment contrast-enhanced T1-weighted (CET1-w) MR images, clinical variables, and follow-up were retrospectively collected. We identified single predictive radiomic feature from primary gross tumor volume (GTVnp) and defined predicted subvolume by calculating voxel-wised feature mapping and within GTVnp. We independently validate predictive value of identified feature and associated predicted subvolume. Results: Only one radiomic feature, gldm_DependenceVariance in 3 mm-sigma LoG-filtered image, was discovered as a signature. In the high-risk group determined by the signature, patients received CCRT + ACT achieved 3-year disease free survival (DFS) rate of 90% versus 57% (HR, 0.20; 95%CI, 0.05–0.94; P = 0.007) for CCRT alone. The multivariate analysis showed patients receiving CCRT + ACT had a HR of 0.21 (95%CI: 0.06–0.68, P = 0.009) for DFS compared to those receiving CCRT alone. The predictive value can also be generalized to the subvolume with multivariate HR of 0.27 (P = 0.017) for DFS. Conclusion: The signature with its heterogeneity mapping could be a reliable and explainable ACT decision-making tool in clinical practice.
Persistent Identifierhttp://hdl.handle.net/10722/346147
ISSN
2023 Impact Factor: 9.7
2023 SCImago Journal Rankings: 1.251

 

DC FieldValueLanguage
dc.contributor.authorTeng, Xinzhi-
dc.contributor.authorZhang, Jiang-
dc.contributor.authorHan, Xinyang-
dc.contributor.authorSun, Jiachen-
dc.contributor.authorLam, Sai Kit-
dc.contributor.authorAi, Qi Yong Hemis-
dc.contributor.authorMa, Zongrui-
dc.contributor.authorLee, Francis Kar Ho-
dc.contributor.authorAu, Kwok Hung-
dc.contributor.authorYip, Celia Wai Yi-
dc.contributor.authorChow, James Chung Hang-
dc.contributor.authorLee, Victor Ho Fun-
dc.contributor.authorCai, Jing-
dc.date.accessioned2024-09-12T00:30:30Z-
dc.date.available2024-09-12T00:30:30Z-
dc.date.issued2023-06-10-
dc.identifier.citationRadiologia Medica, 2023, v. 128, n. 7, p. 828-838-
dc.identifier.issn0033-8362-
dc.identifier.urihttp://hdl.handle.net/10722/346147-
dc.description.abstractPurpose: This study aimed to discover intra-tumor heterogeneity signature and validate its predictive value for adjuvant chemotherapy (ACT) following concurrent chemoradiotherapy (CCRT) in locoregionally advanced nasopharyngeal carcinoma (LA-NPC). Materials and methods: 397 LA-NPC patients were retrospectively enrolled. Pre-treatment contrast-enhanced T1-weighted (CET1-w) MR images, clinical variables, and follow-up were retrospectively collected. We identified single predictive radiomic feature from primary gross tumor volume (GTVnp) and defined predicted subvolume by calculating voxel-wised feature mapping and within GTVnp. We independently validate predictive value of identified feature and associated predicted subvolume. Results: Only one radiomic feature, gldm_DependenceVariance in 3 mm-sigma LoG-filtered image, was discovered as a signature. In the high-risk group determined by the signature, patients received CCRT + ACT achieved 3-year disease free survival (DFS) rate of 90% versus 57% (HR, 0.20; 95%CI, 0.05–0.94; P = 0.007) for CCRT alone. The multivariate analysis showed patients receiving CCRT + ACT had a HR of 0.21 (95%CI: 0.06–0.68, P = 0.009) for DFS compared to those receiving CCRT alone. The predictive value can also be generalized to the subvolume with multivariate HR of 0.27 (P = 0.017) for DFS. Conclusion: The signature with its heterogeneity mapping could be a reliable and explainable ACT decision-making tool in clinical practice.-
dc.languageeng-
dc.publisherSpringer-Verlag Italia-
dc.relation.ispartofRadiologia Medica-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectAdjuvant chemotherapy-
dc.subjectNPC-
dc.subjectRadiomics-
dc.subjectTumor heterogeneity map-
dc.titleExplainable machine learning via intra-tumoral radiomics feature mapping for patient stratification in adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma-
dc.typeArticle-
dc.identifier.doi10.1007/s11547-023-01650-5-
dc.identifier.pmid37300736-
dc.identifier.scopuseid_2-s2.0-85161441832-
dc.identifier.volume128-
dc.identifier.issue7-
dc.identifier.spage828-
dc.identifier.epage838-
dc.identifier.eissn1826-6983-
dc.identifier.issnl0033-8362-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats